Amsterdam-based scaleup Lumicks has secured €20mn from the European Investment Bank (EIB) to accelerate the discovery of immunotherapy drugs for cancer. The venture debt funding will help Lumicks further develop and market its cell avidity analyser, a machine with the potential to transform the way researchers study and develop treatments for Europe’s second most deadly disease. Lumicks’ tech allows scientists to gather real-time data on the bonds between immune cells and cancer cells. Unlike traditional methods, which rely on indirect biomarkers, the analyser precisely measures the actual strength and duration of those interactions directly and in real time. This is…
This story continues at The Next Web